Drug
Tivantinib
Tivantinib: highest development phase Phase 1/2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tivantinib NCT01611857 | Phase 1/2 | Malignant Solid Tumour |
Latest
No recent events.
Follow Tivantinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.